Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 28; p. v142
Main Authors: Mehnert, J.M., Rugo, H.S., O'Neil, B.H., Santoro, A., Schellens, J.H.M., Cohen, R.B., Doi, T., Ott, P.A., Pishvaian, M.J., Puzanov, I., Aung, K.L., Hsu, C., Le Tourneau, C., Soria, J-C., Elez, E., Tamura, K., Gould, M., Zhao, G., Stein, K., Piha-Paul, S.A.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-09-2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdx368